Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
30 1월 2024 - 6:05AM
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial
stage biotechnology company that aims to translate the genetics of
the adaptive immune system into clinical products to diagnose and
treat disease, today announced it will report financial results for
the fourth quarter and full year 2023 after market close on
Wednesday, February 14, 2024. Company management will webcast a
corresponding conference call beginning at 1:30 p.m. Pacific Time /
4:30 p.m. Eastern Time.
Live audio of the webcast will be available on
the “Investors” section of the company website at:
www.adaptivebiotech.com. The webcast will be archived and available
for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage
biotechnology company focused on harnessing the inherent biology of
the adaptive immune system to transform the diagnosis and treatment
of disease. We believe the adaptive immune system is nature’s most
finely tuned diagnostic and therapeutic for most diseases, but the
inability to decode it has prevented the medical community from
fully leveraging its capabilities. Our proprietary immune medicine
platform reveals and translates the massive genetics of the
adaptive immune system with scale, precision and speed. We apply
our platform to partner with biopharmaceutical companies, inform
drug development, and develop clinical diagnostics across our two
business areas: Minimal Residual Disease (MRD) and Immune Medicine.
Our commercial products and clinical pipeline enable the diagnosis,
monitoring, and treatment of diseases such as cancer, autoimmune
disorders, and infectious diseases. Our goal is to develop and
commercialize immune-driven clinical products tailored to each
individual patient.
ADAPTIVE INVESTORSKarina Calzadilla, Vice
President, Investor
Relations201-396-1687investors@adaptivebiotech.com
ADAPTIVE MEDIAErica Jones, Associate Director,
Corporate Communications206-279-2423media@adaptivebiotech.com
Adaptive Biotechnologies (NASDAQ:ADPT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Adaptive Biotechnologies (NASDAQ:ADPT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024